[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613615":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":13,"collaborators":10,"id":17,"slug":18,"hasResults":19,"nctId":20,"briefTitle":21,"officialTitle":21,"acronym":10,"eligibilityCriteria":22,"healthyVolunteers":19,"sex":23,"minAge":24,"maxAge":10,"enrollmentInfo":25,"targetDuration":10,"studyType":28,"phases":10,"briefSummary":29,"conditions":30,"keywords":32,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":10},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"Treated Group",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Untreated Group",{"type":14,"investigatorFullName":15,"investigatorTitle":16,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhang Lei, MD","Chief Physician","100613615","national-multicenter-retrospective-real-world-study-on-the-treatment-status-of-newly-diagnosed-and-persistent-primary-immune-thrombocytopenia-itp-patients-100613615",false,"NCT07268898","National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients","Inclusion Criteria:\n\n* Availability of traceable inpatient medical records;\n\nClinically diagnosed with newly diagnosed or persistent ITP (ITP disease course ≤12 months) between July 2021 and September 2025;\n\nBaseline platelet count \\\u003C30×10⁹\u002FL;\n\nAge ≥6 years;\n\nInclusion of patients regardless of ITP treatment status, encompassing those receiving any ITP-directed therapy (excluding emergency treatments such as platelet transfusion) and untreated patients (who have not received ITP-specific treatments including glucocorticoids, intravenous immunoglobulin, TPO-RAs, splenectomy, and rituximab).\n\nExclusion Criteria:\n\n\\-","ALL","6 Years",{"count":26,"type":27},500,"ESTIMATED","OBSERVATIONAL","This study is a nationwide, multicenter, retrospective, real-world, non-interventional (observational) investigation. It retrospectively collects data on treatment modalities and therapeutic responses in patients with newly diagnosed or persistent immune thrombocytopenia (ITP), documents disease progression in both treated and untreated patients, and records the treatment regimens selected by those receiving therapy. The study aims to observe and evaluate the current treatment landscape for newly diagnosed and persistent ITP patients, while also analyzing the efficacy and safety in the treated population. All patient treatments and disease management are solely based on routine clinical practice and are not influenced by this study.",[31],"Immune Thrombocytopenia (ITP)",[33],"RWS","NOT_YET_RECRUITING","2025-11-25",{"date":37,"type":38},"2025-12-08","ACTUAL",{"date":35,"type":27},{"date":41,"type":27},"2026-06-30",{"name":5,"class":6}]